Urine Bladder Cancer Test Could Triage Cystoscopy
Real-world UK study suggests molecular testing could help prioritize patients with hematuria for urgent bladder investigation
Clinical Scorecard: Urine Bladder Cancer Test Could Triage Cystoscopy
At a Glance
| Category | Detail |
|---|
| Condition | Bladder Cancer |
| Key Mechanisms | Urine-based DNA test using next-generation sequencing to detect mutations associated with bladder cancer. |
| Target Population | Patients with hematuria referred for urgent cystoscopy. |
| Care Setting | Urology departments in the UK National Health Service. |
Key Highlights
- GALEAS Bladder assay detected 71 of 77 bladder cancers.
- Negative predictive value exceeded 99 percent.
- Modeling suggested a reduction of 730 urgent cystoscopies per 1000 patients.
- Assay detected all muscle-invasive cancers and most high-grade cancers.
- Study supports molecular testing as a triage tool, not a replacement for cystoscopy.
Guideline-Based Recommendations
Diagnosis
- Use GALEAS Bladder assay to identify patients needing urgent cystoscopy.
Management
- Negative results can support deferred cystoscopy with appropriate surveillance.
Monitoring & Follow-up
- Patients with positive results should be prioritized for prompt cystoscopy.
Risks
- Incomplete follow-up for patients with positive molecular results but negative standard investigations.
Patient & Prescribing Data
Patients with hematuria referred for cystoscopy.
Molecular testing can guide urgency of cystoscopy.
Clinical Best Practices
- Implement molecular testing as a triage tool in hematuria investigations.
- Ensure appropriate follow-up for patients with positive molecular results.
Related Resources & Content
